Effect of Vitamin C in Autologous Stem Cell Transplantations

• Status: Recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In the study the investigators will randomize patients that receive an autologous stem cell transplantation for myeloma or lymphoma for treatment with vitamin C or placebo during 6 weeks. Primary endpoint will be immune recovery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maastricht University Medical Center
• Treatments: Ascorbic Acid; Vitamins

Criteria

Inclusion Criteria:

• 18 years or older

• written informed consent

• diagnosis of malignant lymphoma or multiple myeloma

• require chemotherapy plus autologous stem cell transplantation as standard of care for the disease at that stage

• central venous catheter in place or planned

Exclusion Criteria:

• inability to understand the nature and extent of the trial and the procedures required

• history of kidney stones

• kidney failure requiring dialysis or eGFR <30 mL/min. (CDK-EPI formula)

• history of G6PD deficiency

• life expectancy < 1 month

• use of immunosuppressive medication other than chemotherapy and corticosteroids